Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during ...

In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this ...

MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on rare liver diseases, has been making significant strides in its product portfolio and market position. With a ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on rare liver diseases, has been making significant strides in its product portfolio and market position. With a market ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified ...

Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis. Ctexli is the first and only ...